Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up

doi:10.3748/wjg.v13.i39.5238

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 39

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2258)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

306

HTML

1507

Figures (1-2)

232

Tables (1-4)

213

Sum=2258

Oct 21, 2007 (publication date) through Nov 11, 2024

Times Cited of This Article

Times Cited (41)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Oct 21, 2007; 13(39): 5238-5244
Published online Oct 21, 2007. doi: 10.3748/wjg.v13.i39.5238

Full Size Figure Download Figure

Figure 2 Kaplan-Meier survival curve for CD patients (n = 40). The cumulative probability of being free of relapse in CD patients with complete response was: 97.2% (CI: 91.8%-100%) at 12 mo, 90.3% (CI: 79.7%-100%) at 24 mo, 81.7% (CI: 66.9%-96.5%) at 36 mo, 73.5% (CI: 53.3%-93.7%) at 48 mo, and 61.3% (CI: 33.6%-88.9%) at 51 mo.

Citation: Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244
URL: https://www.wjgnet.com/1007-9327/full/v13/i39/5238.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i39.5238